North Carolina is currently home to 2618 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Durham, Charlotte, Winston-Salem and Chapel Hill. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Bone, Exercise, Alendronate, and Caloric Restriction
NCT05764733
Recruiting
The purpose of this research is to identify strategies that minimize bone loss that occurs when older adults lose weight. Participation in this research will involve up to nine assessment visits and last up to two years.
Gender:
ALL
Ages:
60 years and above
Trial Updated:
01/29/2025
Locations: Atrium Health Wake Forest Baptist, Winston-Salem, North Carolina
Conditions: Bone Loss
Register for Updates
A Study of Peluntamig (PT217) in Patients with Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
NCT05652686
Recruiting
This is a first-in-human, Phase 1/2, open-label, dose escalation, dose expansion and combination study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of Peluntamig (PT217) as a monotherapy and in combination with chemotherapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/29/2025
Locations: University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
Conditions: Small Cell Lung Cancer (SCLC), Large Cell Neuroendocrine Cancer (LCNEC), Neuroendocrine Prostate Cancer (NEPC), Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC), Neuroendocrine Carcinomas (NEC), Extrapulmonary Neuroendocrine Carcinoma (EP-NEC)
Register for Updates
ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer
NCT05542407
Recruiting
Endometrial cancer (EC) is the fourth most common cancer in United States women, and alarmingly, the frequency and mortality from EC continues to rise, in part due to the obesity epidemic. Obese women with EC have a 6.3-fold increased risk of death from this disease, as compared to their non-obese counterparts. Patients with advanced/recurrent EC are unlikely to be cured by surgery, conventional chemotherapy (paclitaxel + carboplatin is the standard first-line treatment), radiation, or a combina... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
01/29/2025
Locations: Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina
Conditions: Endometrial Cancer, Metastasis
Register for Updates
Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 MAb, Administered Alone and in Combination with a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)
NCT05431270
Recruiting
This is a first-in-human, Phase 1/2, open-label, study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of Mavrostobart (PT199) alone and in combination with a PD-1 inhibitor or chemotherapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/29/2025
Locations: Carolina BioOncology Institute, Huntersville, North Carolina
Conditions: Non Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma
Register for Updates
Enhancing Rural Health Via Cardiovascular Telehealth for Rural Patients Implementation (E-VICTORS)
NCT04617834
Recruiting
This pre-post study will evaluate the implementation of a cardiovascular telehealth platform, which will connect experts from the Wake Forest University Health Sciences (WFUHS) tertiary care center with Wilkes County Emergency Medical Services (WC-EMS) system, Wilkes Medical Center Emergency Department (ED), and The Wilkes County Health Department Public Health Community Clinic (PHCC) to improve cardiovascular care in this rural community.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/29/2025
Locations: Wilkes County Emergency Medical Services, Wilkesboro, North Carolina
Conditions: Cardiovascular Diseases, Acute Coronary Syndrome
Register for Updates
Clinical Trial to Evaluate the Safety and Effectiveness of Using the Tendyne Transcatheter Mitral Valve System for the Treatment of Symptomatic Mitral Regurgitation
NCT03433274
Recruiting
Prospective, controlled, multicenter clinical investigation with four trial cohorts: Randomized, Non-repairable, Severe Mitral Annular Calcification (MAC) and Severe Mitral Annular Calcification Continued Access Protocol (MAC CAP). Subjects in the Randomized cohort will be randomized in a 1:1 ratio to the trial device or to the MitraClip system. Subjects in the Non-repairable, Severe MAC, and Severe MAC CAP cohorts will receive the trial device. The objective of the Clinical Trial to Evaluate t... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/29/2025
Locations: Mission Health & Hospitals, Asheville, North Carolina
Conditions: Mitral Regurgitation, Mitral Insufficiency, Mitral Valve Insufficiency, Cardiovascular Diseases, Valve Disease, Heart, Heart Valve Diseases, Functional Mitral Regurgitation, Degenerative Mitral Valve Disease
Register for Updates
A Randomized Controlled Trial to Test the Effects Oxytocin and Vibration Have on Heat Pain Threshold After UV-B Burn
NCT06651476
Recruiting
This study aims to answer the question: Does oxytocin increase the pain threshold on thermal heat pain in the presence of vibration on an area of skin exposed to a mild sunburn?
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
01/28/2025
Locations: Atrium Health Wake Forest Baptist Medical Center, Winston-Salem, North Carolina
Conditions: Sunburn
Register for Updates
A Trial to Learn if Dupilumab is Safe for and Helps Adult and Adolescent Participants With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis
NCT05831176
Recruiting
The study is researching an experimental drug called dupilumab. The study is focused on participants with active eosinophilic gastritis (EoG) with or without eosinophilic duodenitis (EoD). Participants with EoD only are not eligible for enrollment. EoG and EoD are uncommon, persistent, allergic/immune diseases in which eosinophils (a type of white blood cell) gather in large numbers in the stomach and small intestine and cause inflammation and damage. The aim of the study is to evaluate the eff... Read More
Gender:
ALL
Ages:
12 years and above
Trial Updated:
01/28/2025
Locations: University of North Carolina, Chapel Hill, North Carolina
Conditions: Eosinophilic Gastritis, Eosinophilic Duodenitis, Eosinophilic Gastrointestinal Disease
Register for Updates
Testing the Role of FDG-PET/CT to Predict Response to Therapy Prior to Surgery for HER2-positive Breast Cancer, The DIRECT Trial
NCT05710328
Recruiting
This phase II trial tests how well an imaging procedure called fludeoxyglucose F-18 (FDG) positron emission tomography/computed tomography (PET/CT) works in predicting response to standard of care chemotherapy prior to surgery in patients with HER2-positive stage IIa-IIIc breast cancer. FDG is a radioactive tracer that is given in a vein before PET/CT imaging and helps to identify areas of active cancer. PET and CT are imaging techniques that make detailed, computerized pictures of areas inside... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/28/2025
Locations: UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina
Conditions: Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, HER2-Positive Breast Carcinoma, Invasive Breast Carcinoma
Register for Updates
Appalachian Partnership to Reduce Disparities (Aim 2)
NCT04378439
Recruiting
By combining two strategies (i.e., peer navigation and mHealth) into a complete, culturally compatible, bilingual intervention to increase the use of needed HIV, STI, and HCV prevention and care services among racially/ethnically diverse GBMSM and transgender women in rural Appalachia. Study Investigators anticipate that participants in the intervention group, relative to counterparts in the delayed-intervention group, will demonstrate increased HIV, STI, and HCV testing.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/28/2025
Locations: Wake Forest University Health Sciences, Winston-Salem, North Carolina
Conditions: HIV/AIDS, STI, HCV
Register for Updates
Improving Pain Control in Paraesophageal Hernia Repair: Intravenous Lidocaine Versus Placebo
NCT04096170
Recruiting
We aim to study the impact of perioperative IV lidocaine on postoperative pain control in patients undergoing paraesophageal hernia repair. This is in the context of an established ERAS protocol. We wish to study the effect of IV Lidocaine on postoperative short and long-term outcomes, including patients' length of stay postoperative mortality, morbidity, and quality of life. We will compare this to our standard pain management.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/28/2025
Locations: Atrium Health - Carolinas Medical Center, Charlotte, North Carolina
Conditions: Hernia, Paraesophageal
Register for Updates
Modern Immunotherapy in BCG-Unresponsive, BCG-Relapsing and High Risk BCG-Naive Non-Muscle Invasive Urothelial Carcinoma of the Bladder
NCT03317158
Recruiting
Upon successful screening and registration, enrollment to durvalumab monotherapy (cohort 1) will begin. If DLT criteria outlined in the protocol are exceeded with durvalumab monotherapy (cohort 1), the study will close. Provided the safety of durvalumab monotherapy is established, enrollment to combination regimen cohorts will proceed. Cohorts will simultaneously enroll in parallel to each other with patients assigned to cohorts based on patient slot availability and study site choice of radiati... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/28/2025
Locations: University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
Conditions: Urothelial Carcinoma, Bladder Cancer
Register for Updates